Vernalis plc Initiates Phase 2a Trial for V3381 in Neuropathic Pain

Vernalis plc, a leading pharmaceutical company, has initiated a phase 2a trial of its novel drug candidate, V3381, in patients with neuropathic pain caused by long-standing diabetes. This significant development marks a crucial step forward in the company's efforts to address a debilitating condition that affects millions worldwide. The trial, which will take place in the United States and Canada, aims to assess the safety, pharmacokinetics, and preliminary efficacy of repeat dosing of V3381, with the goal of providing relief to patients suffering from this chronic condition.

Key Takeaways:

Vernalis plc has initiated a phase 2a trial of V3381 in approximately 30 patients with neuropathic pain caused by long-standing diabetes.
The randomized, double-blind, crossover study is designed to assess the safety, pharmacokinetics, and preliminary efficacy of repeat dosing of V3381.
Efficacy will be assessed using a numerical point pain rating scale recorded through daily diaries.
V3381 is a novel drug candidate with dual mechanisms of action targeting both the central and peripheral nervous systems.
The trial is planned to complete within 12 months, and V3381 has previously undergone evaluation in preclinical and phase 1 clinical studies.
Vernalis plc has worldwide rights to V3381 and is building its franchise in pain management.
Simon Sturge, CEO of Vernalis, expressed hope that V3381 may ultimately prove to be an effective treatment for neuropathic pain.

Statistics:

30 patients will participate in the phase 2a trial of V3381.
The trial is expected to complete within 12 months.
Neuropathic pain affects millions of people worldwide.
V3381 has been previously evaluated in preclinical (no specific number mentioned) and phase 1 (no specific number mentioned) clinical studies.

Sources:

Health & Medicine Week editors via NewsRx.com
Vernalis plc press release (exact source not provided in the original text)